Improving Workforce Participation and Well-Being in Individuals With Multiple Sclerosis - A Feasability Study

NCT07380295 | Recruiting

• 1 other identifier: MSCogWork3
• Study Type: observational
• Target: 20
• Locations: 1 country
• Sites: 1

Brief Summary

Multiple sclerosis (MS) is a chronic neurodegenerative disease and a leading cause of reduced workforce participation due to neurological illness in Western countries. Over the past 30 years, new treatments have reduced symptom burden, allowing patients to stay in the workforce longer. However, fatigue and cognitive impairments remain major barriers to work capacity. This project aims to preliminary examine the impact of cognitive function on work ability, and assess the role of neuropsychologists in multidisciplinary rehabilitation teams. It consists of a feasibility study evaluating the integration of neuropsychological interventions into teambased work-oriented rehabilitation. The specific research questions are:

1. 1.How can neuropsychological interventions be integrated into team-based work-oriented rehabilitation?
2. 2.How do these interventions relate to work ability and well-being in individuals with MS? The investigators plan to collect data on 20 consecutively patients with MS before, 6 months after and 2 years after a neuropsychological testing and intervention. The patients are being followed on measures related to well-being and work ability. Data from the neuropsychological assessment, other rehabilitation interventions as well as data related to treatment and progress of MS are also collected.

Conditions

Multiple Sclerosis

Outcome Measures

Primary Outcomes (4)

• Work participation

  Percentage of full-time work. 100 % full-time work and 0% is not working at all.

  From baseline to 2-year follow-up

• Hospital anxiety and depression scale

  Self-assessment of anxiety and depression. Consists of two scales measuring the probability of having anxiety and depression respectively. Min score 0, max 21 for each scale. Higher scores indicate higher probability of anxiety/depression.

  From baseline to 2-year follow-up

• WHO-5 Well-Being Index

  Overall rating of well-being. The WHO-5 score range is a raw score of 0-25, which is then multiplied by 4 to get a percentage score of 0-100. Higher score indicates higher well-being.

  From baseline to 2-year follow-up

• Brief index of job satisfaction

  The Brief Index of Affective Job Satisfaction (BIAJS) has a score range of 1 to 5 for each of its four items, based on a 5-point Likert scale where 1 is "strongly disagree" and 5 is "strongly agree". The total BIAJS score is the sum of these four items, resulting in a possible range from 4 to 20, with higher scores indicating greater affective job satisfaction.

  From baseline to 2-year follow-up

Secondary Outcomes (2)

• Quantative work demands

  From baseline to 2-year follow-up

• Can-Work-S

  From baseline to 2-year follow-up

Study Arms (1)

Patients with multiple scleroris of working age

Patients with MS and of working age (18-65) referred to neuropsychological evaluation.

Eligibility Criteria

• Age: 18 Years - 65 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients of working age with MS in Region Gävleborg who are refered for a neuropsychological assessment and who are not suffering from other diagnosis which impact their work ability to a large extent.

You may qualify if:

• Multiple sclerosis Age between 18-65 Refered to neuropsychological assessment at the Neurology departement at Gävle Hospital -

You may not qualify if:

• Other diagnosis hindering work participation more than MS

Sponsors & Collaborators

• Region Gävleborg: lead
• University of Gavle: collaborator

Study Sites (1)

Gävle hospital

Gävle, Sweden

RECRUITING

MeSH Terms

Conditions

Multiple Sclerosis

Condition Hierarchy (Ancestors)

Demyelinating Autoimmune Diseases, CNS; Autoimmune Diseases of the Nervous System; Nervous System Diseases; Demyelinating Diseases; Autoimmune Diseases; Immune System Diseases

Central Study Contacts

Natascha Ekdahl

CONTACT

+4626278023; natascha.ekdahl@regiongavleborg.se

Study Design

• Study Type: observational
• Observational Model: COHORT
• Time Perspective: PROSPECTIVE
• Target Duration: 2 Years
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: September 22, 2025
• First Posted: February 2, 2026
• Study Start: July 22, 2025
• Primary Completion (Estimated): September 1, 2028
• Study Completion (Estimated): September 1, 2028
• Last Updated: February 2, 2026

Record last verified: 2026-01

Data Sharing

• IPD Sharing: Will not share

Locations

SE (1)